1. Bode-Boger SM, Boger RH, Kııhıı M, Radermacher J, Frohlich JC: Recombinant human erythropoietin enhan-ces vasoconstrictor lone via endolhelin-I and constridor prostonoids. Kidııcy Int 50:1255 (19%).
2. Dunu CJ, Markham A: Epoetin bela: A rcvieıv of its pharmacologieal properties and ciinical ııse in Ihe mana-gcmeııl of aııaemiu associatcd wilh chrnnic rcnal failine. Drugs5I:299(i996).
3. Edmıınds ME, Wails J Tucker B, Baker LR, Tomson CR, Ward M, Cunningham J, Moore R, VVinearls CG: Seizıı-res in haemodialysİs palients treated vvith recombinant human erylhıopoietîn. Nephrol Dial Transplant 4:1065 (1989).
4. Eggena P, Willsey P, Jamgolehian N, Truckcnbrod L, HLI MS, Barrett JD, Eggena MP. Clegg K, Nakhoul F, Lee DB: Infuence of recombinant huıııan erythropoietin on blood pressure and lissue lenin-angiolensin systems. Am JPhysiol 261:642(1991).
5. Eschbach JW, Abduhade MH, Browne JK: Recombinant human erythropoietin in severe anemia patients with end-stagc rcnal disease: Results of phasc 111 multicentcr inal. Aıın fntem Med 111:992 (İ989).
6. Eschbach JW, Egric JC, Downing MR, Brovvn JK, Adamson JW: Correction of anemia of end- stage disease vvith recombinant erythropoietin. N Engl J Med 316:73 (1987).
7. Jabs K, Harmon WE: Recombinant human eıythropocilitı therapy in children on dialysis. Adv Rcnal Replace Thcr 3:24(1996).
8. Konıatsu Y, Ito K: Erylhropoieiin-associaled hypertensİ-on among pediatric dialysis patients. Adv Perit Dial 8:448(1992).
9. Marrero MB, Vencma RC, Heping M, Lİng B, Eton DC: Erythropoietin receptor- operated caleium channels: Ac-tivalion by phospholipase C-gama 1. Kidtıey Int 53:1259 (1998).
10. Nisscnson AR: Milcstones in nephrology: Guest com-mentary. J Am Soc Nephrol 11:589 (2000).
11. Taylor J, Pahl M, Rajpoot D: Erythropoietin-induced hypertensive encephalopathy in a child: Possible mceha-nisms. Dial Transplanl 31:170 (2002).
12. Tomson CRV, Vcnning MC, Ward MK: Blood pressure and erythropoietin. Lancet 1:351 (1988).
13. Vaziri ND, Zhou XJ, Naqvi F, Smith J, Oveisi T, Wang ZQ, Purdy RE: Role of nilric oxide resistance in erythro-poietin-induced hypertcnsion in rats vvith ehronic renal failine. Am S Plıysiol 271 :E113 (1996).
14. Winearîs CG, Pippard MJ, Dovvning MR, Oliver DO, Ri-ed C, Cotes PM: Effects of human erythropoietin derived from recombinant DNA on the anemia of patients main-tainedby chroııic hemodialysis. Lancet 2:1175 (1986).
Thank you for copying data from http://www.arastirmax.com
